Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hizentra higher infusion parameter safety study in primary immunodeficiency
2016-003799-33Phase 4
- Sponsor
- CSL Behring
- Start
- Jan 2017
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of polyvalent human immunoglobulin in Immunogenetic disorder, common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), sponsored by CSL Behring. Primary endpoint: Percentage of Responders.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Immunogenetic disordercommon variable immunodeficiency (CVID)X-linked agammaglobulinemia (XLA)
Beyond the preview
Go deeper on 2016-003799-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003799-33.